Cargando…

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody

An 80-year-old woman with malignant melanoma received 20 cycles of anti-programmed death 1 (PD-1) antibody (nivolumab) treatment and showed normal glucose tolerance. Three weeks after switching to anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody (ipilimumab), her plasma glucose lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiba, Michiru, Inaba, Hidefumi, Ariyasu, Hiroyuki, Kawai, Shintaro, Inagaki, Yuko, Matsuno, Shohei, Iwakura, Hiroshi, Yamamoto, Yuki, Nishi, Masahiro, Akamizu, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096029/ https://www.ncbi.nlm.nih.gov/pubmed/29491310 http://dx.doi.org/10.2169/internalmedicine.9518-17

Ejemplares similares

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report
por: Kitahara, Chie, et al.
Publicado: (2020)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
por: Sone, Kenbun, et al.
Publicado: (2022)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

SAT-433 The Influence of Thyroid Autoimmunity on Pregnancy Outcome in Infertile Women
por: Takeshima, Ken, et al.
Publicado: (2020)

Predominant Improvement of Alpha Cell Function after Steroid Therapy in a Patient with Autoimmune Pancreatitis: Case Report
por: Takeshima, Ken, et al.
Publicado: (2018)

Intrinsic insulin secretion capacity might be preserved by discontinuing anti‐programmed cell death protein 1 antibody treatment in ‘anti‐programmed cell death protein 1 antibody‐induced’ fulminant type 1 diabetes
por: Sakai, Gota, et al.
Publicado: (2018)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
por: Jolly, Elaine C., et al.
Publicado: (2009)

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
por: Azuma, Takeshi, et al.
Publicado: (2021)

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice
por: Omiya, Toshinobu, et al.
Publicado: (2020)

High Levels of Soluble Ctla-4 Are Present in Anti-Mitochondrial Antibody Positive, but Not in Antibody Negative Patients with Primary Biliary Cirrhosis
por: Saverino, Daniele, et al.
Publicado: (2014)

Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
por: Persson, Jonas, et al.
Publicado: (2011)

New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy
por: Waight, Jeremy D., et al.
Publicado: (2018)

Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
por: Takahashi, Keita, et al.
Publicado: (2021)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

Autosomal Dominant Hypocalcemia With Atypical Urine Findings Accompanied by Novel CaSR Gene Mutation and VitD Deficiency
por: Tsuji, Tomoya, et al.
Publicado: (2020)

Graves' Disease in Pediatric and Elderly Patients with 22q11.2 Deletion Syndrome
por: Ueda, Yoko, et al.
Publicado: (2017)

Radiation Dose Escalation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma
por: Takenaka, Wataru, et al.
Publicado: (2020)

A Fulminant Case of Demyelinating Encephalitis With Extensive Cortical Involvement Associated With Anti-MOG Antibodies
por: Hochmeister, Sonja, et al.
Publicado: (2020)

Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use
por: Russe-Russe, Jose R, et al.
Publicado: (2021)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

Association of anti‐gangliosides antibodies and anti‐CMV antibodies in Guillain–Barré syndrome
por: Wang, Lijuan, et al.
Publicado: (2017)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
por: Bertrand, Anne, et al.
Publicado: (2015)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin
por: Kuniyoshi, Noriyuki, et al.
Publicado: (2019)

Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice
por: Ueda, Yoko, et al.
Publicado: (2018)

Fulminant Respiratory Failure Caused by Anti-asparaginyl tRNA Synthetase (Anti-KS) Antibody Syndrome-related Interstitial Lung Disease
por: Oda, Naohiro, et al.
Publicado: (2022)

Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission
por: Muto, Reiko, et al.
Publicado: (2020)

Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody
por: Bai, Yunfei, et al.
Publicado: (2023)

Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
por: Shibayama, Yui, et al.
Publicado: (2019)

The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
por: Jensen, Benjamin A. H., et al.
Publicado: (2013)

Nicotinic acetylcholine receptor signaling regulates inositol‐requiring enzyme 1α activation to protect β‐cells against terminal unfolded protein response under irremediable endoplasmic reticulum stress
por: Ishibashi, Tatsuya, et al.
Publicado: (2020)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l7jla45ld40a934t1u0skdv4vt